Bank of Nova Scotia lessened its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 91.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,806 shares of the medical research company’s stock after selling 20,198 shares during the period. Bank of Nova Scotia’s holdings in Bio-Rad Laboratories were worth $893,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors also recently bought and sold shares of the company. HM Payson & Co. acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth about $28,000. Cambridge Trust Co. boosted its stake in shares of Bio-Rad Laboratories by 170.0% during the first quarter. Cambridge Trust Co. now owns 54 shares of the medical research company’s stock worth $30,000 after buying an additional 34 shares during the period. Parkside Financial Bank & Trust boosted its stake in shares of Bio-Rad Laboratories by 80.0% during the second quarter. Parkside Financial Bank & Trust now owns 54 shares of the medical research company’s stock worth $26,000 after buying an additional 24 shares during the period. Tcwp LLC acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth about $48,000. Finally, Rosenberg Matthew Hamilton boosted its stake in shares of Bio-Rad Laboratories by 65.0% during the second quarter. Rosenberg Matthew Hamilton now owns 99 shares of the medical research company’s stock worth $50,000 after buying an additional 39 shares during the period. Institutional investors and hedge funds own 64.33% of the company’s stock.
Bio-Rad Laboratories Trading Up 0.9 %
Shares of Bio-Rad Laboratories stock opened at $398.12 on Friday. Bio-Rad Laboratories, Inc. has a 12-month low of $344.63 and a 12-month high of $783.94. The company has a current ratio of 5.50, a quick ratio of 4.30 and a debt-to-equity ratio of 0.14. The stock has a market cap of $11.87 billion, a PE ratio of -1.97 and a beta of 0.92. The company has a 50-day moving average of $410.79 and a two-hundred day moving average of $475.91.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on BIO shares. Credit Suisse Group decreased their target price on shares of Bio-Rad Laboratories from $715.00 to $640.00 and set an “outperform” rating for the company in a research note on Friday, October 28th. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, November 9th. Finally, TheStreet cut shares of Bio-Rad Laboratories from a “c” rating to a “d+” rating in a report on Thursday, October 27th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $680.00.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
- Get a free copy of the StockNews.com research report on Bio-Rad Laboratories (BIO)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.